Previous 10 | Next 10 |
The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with this event. For further details see: Regeneron Pharmaceuticals (REGN) Presents at the ESMO Congress 2022 - Slideshow
Alnylam ( ALNY ) and Regeneron ( NASDAQ: REGN ) announced Thursday that early Phase 1 data for ALN-HSD, an experimental therapy for liver disease nonalcoholic steatohepatitis (NASH), supported their plans to begin a Phase 2 trial for the candidate later this year. The co...
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers PR Newswire Target knockdown and safety results support continued clinical development Regeneron and Alnylam intend to initiate a Phase 2 s...
Summary Regeneron has grown revenues from $1.3bn in 2012, to >$15bn in 2021 - largely thanks to its incredible eye disorder drug Eylea. The company's revenues will fall this year with no contribution from COVID antibody cocktail REGEN-Cov - which earned $5.8bn in FY21. That...
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022, 11:05 AM ET Company Participants Ryan Crowe - VP of IR Leonard Schleifer - Founder, President and CEO Marion McCourt - EVP of Commercial Confe...
Regeneron Pharmaceuticals, Inc. (REGN) ESMO 2022 Investor Event September 12, 2022 08:00 AM ET Company Participants Ryan Crowe - Head, IR David Weinreich - EVP, Global Clinical Development Israel Lowy - SVP, Translational Sciences & Oncology Justin Holko ...
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM PR Newswire 63% combined pathologic response rate for neoadjuvant Libtayo monotherapy in stage II to IV resectable C...
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors PR Newswire Positive clinical data presented in a mini...
Summary Today, we put Busted IPO Trevi Therapeutics in the spotlight for the first time ever. The company's primary drug candidate Haduvio is moving towards late-stage development as a treatment for prurigo nodularis as well as chronic cough in adults with idiopathic pulmonary fib...
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors PR Newswire First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered adva...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...